Cost of the Personal

While genome sequencing may enable more personalized medicine, an article in Vancouver Sun examines how it may also lead to more expensive drugs. Because therapeutics targeted against certain genetic mutations may only then be effective in a sliver of the population, Randy Shore writes in the Sun that such 'orphan drugs' could command prices ranging between $100,000 and $1 million a year for each patient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.